Albuminuria and decline in cognitive function: The ONTARGET/TRANSCEND studies.

BACKGROUND Microvascular disease of the kidney (manifesting as albuminuria) and of the brain (manifesting as cognitive decline) may share a common pathogenesis. Gaining an understanding of the concomitant history of these 2 conditions may inform clinical practice and lead to novel prevention and treatment approaches. METHODS A total of 28 384 participants with vascular disease or diabetes mellitus were examined. At baseline and year 5, participants underwent a Mini-Mental State Examination (MMSE) and urine testing for albumin excretion. Multivariable logistic regression was used to determine the association between albumin excretion and MMSE score, cross-sectionally and prospectively, and whether angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker use modified the association. RESULTS Compared with participants with normoalbuminuria, those with microalbuminuria (odds ratio [OR], 1.26; 95% confidence interval [CI], 1.11-1.44]) and macroalbuminuria (1.49; 1.20-1.85) were more likely to have a reduced MMSE score (<24). On follow-up, participants with baseline albuminuria had increased odds of cognitive decline (decrease in MMSE score ≥3 points) compared with those with normoalbuminuria (microalbuminuria: OR, 1.22; 95% CI, 1.07-1.38; macroalbuminuria: 1.21; 0.94-1.55). Participants who developed new albuminuria had increased odds of cognitive decline during follow-up compared with those who remained normoalbuminuric (new microalbuminuria: OR, 1.30; 95% CI, 1.12-1.52; new macroalbuminuria: 1.77; 1.24-2.54). Participants with baseline macroalbuminuria treated with an angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker had lower odds of MMSE decline than participants treated with placebo. CONCLUSION Factors that contribute to albuminuria may contribute to cognitive decline, supporting the notion that both conditions share a common microvascular pathogenesis. Trial Registration clinicaltrials.gov Identifier: NCT00153101.

[1]  E. Barrett-Connor,et al.  A prospective study of albuminuria and cognitive function in older adults: the Rancho Bernardo study. , 2010, American journal of epidemiology.

[2]  S. Yusuf,et al.  Effect of Telmisartan on Renal Outcomes: A Randomized Trial , 2010 .

[3]  J. Williamson,et al.  Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. , 2009, Archives of internal medicine.

[4]  Lars E. Rydn,et al.  Effect of Telmisartan on Renal Outcomes , 2009, Annals of Internal Medicine.

[5]  L. Price,et al.  Albuminuria, cognitive functioning, and white matter hyperintensities in homebound elders. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  W. Elliott.  Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial , 2009 .

[7]  G. Mitchell.  Effects of central arterial aging on the structure and function of the peripheral vasculature: implications for end-organ damage. , 2008, Journal of applied physiology.

[8]  R. Clarnette,et al.  Predictors of Cognitive Decline in Older Individuals With Diabetes , 2008, Diabetes Care.

[9]  G. Paolisso,et al.  Arterial stiffness and cognition in elderly persons with impaired glucose tolerance and microalbuminuria. , 2008, The journals of gerontology. Series A, Biological sciences and medical sciences.

[10]  S. Yusuf,et al.  Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial , 2008, The Lancet.

[11]  L. Kuller,et al.  Albuminuria and dementia in the elderly: a community study. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  J. Goch,et al.  Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study , 2008, Journal of hypertension.

[13]  W. Ahmad.  Effect of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial: The Telmisartan Randomised Assessment Study in ACE intolerant subjects with cardiovascular Disease (TRANSCEND) , 2008 .

[14]  S. Yusuf,et al.  Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.

[15]  A. Kshirsagar,et al.  Microalbuminuria, peripheral artery disease, and cognitive function. , 2008, Kidney international.

[16]  Massimo Filippi,et al.  The effect of white matter lesions on cognition in the elderly—small but detectable , 2007, Nature Clinical Practice Neurology.

[17]  Christian Enzinger,et al.  Section Editor: Progression of Leukoaraiosis and Cognition , 2022 .

[18]  T. Berzin,et al.  Microvascular injury and blood–brain barrier leakage in Alzheimer's disease , 2007, Neurobiology of Aging.

[19]  R. Klein,et al.  Retinal Microvascular Signs, Cognitive Function, and Dementia in Older Person: The Cardiovascular Health Study , 2007, Stroke.

[20]  Tom Greene,et al.  Assessing kidney function--measured and estimated glomerular filtration rate. , 2006, The New England journal of medicine.

[21]  R. Fogari,et al.  Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients , 2006, Journal of Human Hypertension.

[22]  J. Williamson,et al.  Cognitive decline and dementia in diabetes—systematic overview of prospective observational studies , 2005, Diabetologia.

[23]  S. Yusuf,et al.  Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Int , 2004, American heart journal.

[24]  Neil Chapman,et al.  Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. , 2003, Archives of internal medicine.

[25]  A. Hofman,et al.  The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial , 2003, Journal of hypertension.

[26]  A. Garg,et al.  Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. , 2003, Kidney international.

[27]  H. Grossniklaus.  Cerebral white matter lesions, retinopathy, and incident clinical stroke. Wong TY,∗ Klein R, Sharrett AR, Couper DJ, Klein BEK, Liao DP, Hubbard LD, Mosley TH, for the ARIC investigators. JAMA 2002;288:67–74 , 2002 .

[28]  R. Klein,et al.  Cerebral white matter lesions, retinopathy, and incident clinical stroke. , 2002, JAMA.

[29]  R. Klein,et al.  Retinal Microvascular Abnormalities and Cognitive Impairment in Middle-Aged Persons: The Atherosclerosis Risk in Communities Study , 2002, Stroke.

[30]  D. Royall,et al.  Alzheimer disease as a vascular disorder: nosological evidence. , 2002, Stroke.

[31]  J. C. Torre,et al.  Alzheimer Disease as a Vascular Disorder: Nosological Evidence , 2002 .

[32]  P. Luiten,et al.  Cerebral microvascular pathology in aging and Alzheimer's disease , 2001, Progress in Neurobiology.

[33]  M. Steffes,et al.  An overview of renal pathology in insulin-dependent diabetes mellitus in relationship to altered glomerular hemodynamics. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[34]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.